Akebia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Akebia Therapeutics's estimated annual revenue is currently $235M per year.
- Akebia Therapeutics received $85.0M in venture funding in March 2018.
- Akebia Therapeutics's estimated revenue per employee is $783,333
- Akebia Therapeutics's total funding is $340.9M.
Employee Data
- Akebia Therapeutics has 300 Employees.
- Akebia Therapeutics grew their employee count by -5% last year.
Akebia Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Sales | Reveal Email/Phone |
2 | SVP, CFO and Treasurer | Reveal Email/Phone |
3 | SVP, Commercial | Reveal Email/Phone |
4 | SVP Research and Development and Chief Medical Officer | Reveal Email/Phone |
5 | VP, Financial Planning & Analysis | Reveal Email/Phone |
6 | VP, Program Executive (Auryxia GM) | Reveal Email/Phone |
7 | SVP, Quality, Manufacturing & Supply Chain | Reveal Email/Phone |
8 | VP, R&D Operations and External Collaborations | Reveal Email/Phone |
9 | VP, Supply Chain, Procurement and Sourcing | Reveal Email/Phone |
10 | SVP, Strategy, Planning & Alliance Management | Reveal Email/Phone |
Akebia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Akebia Therapeutics?
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease. For more information, please visit our website at www.akebia.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$340.9M
Total Funding
300
Number of Employees
$235M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Akebia Therapeutics News
After safety concerns derailed an approval of Akebia Therapeutics' blockbuster hopeful vadadustat late last month, the company warned that a restructuring...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on. News provided by. Akebia Therapeutics.
The FDA rejected Akebia Therapeutics' anemia drug vadadustat for use in patients with chronic kidney disease, citing concerns about vascular...
CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Of ...
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present at the Jefferies London Heal ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $79M | 305 | 70% | $81M |
#2 | $104.8M | 305 | 26% | N/A |
#3 | $92.9M | 306 | 7% | N/A |
#4 | $50.5M | 311 | -6% | N/A |
#5 | $81.6M | 311 | 5% | N/A |
Akebia Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-12-22 | $15.1M | A | Article | |
| 2009-07-29 | $16.0M | Undisclosed | Novartis Bioventures Ltd, Venture Investors LLC | Article |
| 2011-04-27 | $22.0M | Undisclosed | Novartis Venture Fund, Venture Investors LLC | Article |
| 2012-01-10 | $4.1M | Series B | Novartis Bioventures, Venture Investors | Article |
| 2013-06-05 | $41.0M | C | Satter Investment Management L | Article |
| 2015-04-24 | $64.6M | Undisclosed | UBS Investment Bank | Article |
| 2017-07-07 | $67.0M | Undisclosed | Morgan Stanley | Article |
| 2018-03-26 | $85.0M | Undisclosed | Morgan Stanley | Article |